nodes	percent_of_prediction	percent_of_DWPC	metapath
Sulindac—PTGS1—malignant glioma	0.374	0.636	CbGaD
Sulindac—PTGS2—malignant glioma	0.214	0.364	CbGaD
Sulindac—CYP1A2—Carmustine—malignant glioma	0.0518	1	CbGbCtD
Sulindac—MAPK3—endothelium—malignant glioma	0.00515	0.0681	CbGeAlD
Sulindac—MAPK3—blood vessel—malignant glioma	0.00475	0.0628	CbGeAlD
Sulindac—AKR1B1—embryo—malignant glioma	0.00391	0.0517	CbGeAlD
Sulindac—AKR1B1—retina—malignant glioma	0.00346	0.0457	CbGeAlD
Sulindac—PTGDR2—cerebellum—malignant glioma	0.00332	0.0439	CbGeAlD
Sulindac—AKR1B1—telencephalon—malignant glioma	0.00318	0.042	CbGeAlD
Sulindac—MAPK3—embryo—malignant glioma	0.00283	0.0375	CbGeAlD
Sulindac—PTGDR2—brain—malignant glioma	0.0027	0.0357	CbGeAlD
Sulindac—MAPK3—retina—malignant glioma	0.00251	0.0331	CbGeAlD
Sulindac—PPARD—telencephalon—malignant glioma	0.0025	0.033	CbGeAlD
Sulindac—AKR1B1—medulla oblongata—malignant glioma	0.0025	0.033	CbGeAlD
Sulindac—MAPK3—telencephalon—malignant glioma	0.0023	0.0305	CbGeAlD
Sulindac—AKR1B1—midbrain—malignant glioma	0.00228	0.0302	CbGeAlD
Sulindac—AKR1B1—spinal cord—malignant glioma	0.00223	0.0294	CbGeAlD
Sulindac—MAPK3—medulla oblongata—malignant glioma	0.00181	0.0239	CbGeAlD
Sulindac—AKR1B1—central nervous system—malignant glioma	0.00181	0.0239	CbGeAlD
Sulindac—PPARD—midbrain—malignant glioma	0.0018	0.0237	CbGeAlD
Sulindac—AKR1B1—cerebellum—malignant glioma	0.00177	0.0233	CbGeAlD
Sulindac—MAPK3—midbrain—malignant glioma	0.00166	0.0219	CbGeAlD
Sulindac—Stupor—Carmustine—malignant glioma	0.00163	0.0242	CcSEcCtD
Sulindac—MAPK3—spinal cord—malignant glioma	0.00161	0.0213	CbGeAlD
Sulindac—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00159	0.0236	CcSEcCtD
Sulindac—Cholestasis—Temozolomide—malignant glioma	0.00155	0.023	CcSEcCtD
Sulindac—AKR1B1—brain—malignant glioma	0.00143	0.019	CbGeAlD
Sulindac—PPARD—central nervous system—malignant glioma	0.00142	0.0188	CbGeAlD
Sulindac—PTGS1—endothelium—malignant glioma	0.0014	0.0185	CbGeAlD
Sulindac—PPARD—cerebellum—malignant glioma	0.00139	0.0184	CbGeAlD
Sulindac—PTGS2—endothelium—malignant glioma	0.00134	0.0177	CbGeAlD
Sulindac—MAPK3—central nervous system—malignant glioma	0.00131	0.0173	CbGeAlD
Sulindac—Leukocytosis—Carmustine—malignant glioma	0.0013	0.0192	CcSEcCtD
Sulindac—PTGS1—blood vessel—malignant glioma	0.00129	0.0171	CbGeAlD
Sulindac—MAPK3—cerebellum—malignant glioma	0.00128	0.0169	CbGeAlD
Sulindac—Hearing impaired—Temozolomide—malignant glioma	0.00124	0.0183	CcSEcCtD
Sulindac—PTGS2—blood vessel—malignant glioma	0.00123	0.0163	CbGeAlD
Sulindac—Depressed level of consciousness—Carmustine—malignant glioma	0.00118	0.0174	CcSEcCtD
Sulindac—Depressed level of consciousness—Temozolomide—malignant glioma	0.00114	0.0168	CcSEcCtD
Sulindac—PPARD—brain—malignant glioma	0.00113	0.0149	CbGeAlD
Sulindac—Coma—Carmustine—malignant glioma	0.00111	0.0165	CcSEcCtD
Sulindac—Aplastic anaemia—Temozolomide—malignant glioma	0.00111	0.0164	CcSEcCtD
Sulindac—Gynaecomastia—Carmustine—malignant glioma	0.00109	0.0161	CcSEcCtD
Sulindac—MAPK3—brain—malignant glioma	0.00104	0.0137	CbGeAlD
Sulindac—Gastroenteritis—Temozolomide—malignant glioma	0.000966	0.0143	CcSEcCtD
Sulindac—Vascular purpura—Temozolomide—malignant glioma	0.000957	0.0141	CcSEcCtD
Sulindac—Hepatic failure—Temozolomide—malignant glioma	0.000952	0.0141	CcSEcCtD
Sulindac—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000907	0.0134	CcSEcCtD
Sulindac—Purpura—Temozolomide—malignant glioma	0.000888	0.0131	CcSEcCtD
Sulindac—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000886	0.0131	CcSEcCtD
Sulindac—SLC22A6—brain—malignant glioma	0.000796	0.0105	CbGeAlD
Sulindac—Muscular weakness—Carmustine—malignant glioma	0.000781	0.0116	CcSEcCtD
Sulindac—Toxic epidermal necrolysis—Temozolomide—malignant glioma	0.000771	0.0114	CcSEcCtD
Sulindac—Muscular weakness—Temozolomide—malignant glioma	0.000755	0.0112	CcSEcCtD
Sulindac—PTGS2—embryo—malignant glioma	0.000736	0.00973	CbGeAlD
Sulindac—Pancytopenia—Carmustine—malignant glioma	0.000727	0.0107	CcSEcCtD
Sulindac—Sweating increased—Temozolomide—malignant glioma	0.000721	0.0107	CcSEcCtD
Sulindac—Neutropenia—Carmustine—malignant glioma	0.000716	0.0106	CcSEcCtD
Sulindac—Pancytopenia—Temozolomide—malignant glioma	0.000702	0.0104	CcSEcCtD
Sulindac—Neutropenia—Temozolomide—malignant glioma	0.000692	0.0102	CcSEcCtD
Sulindac—Dysuria—Temozolomide—malignant glioma	0.000692	0.0102	CcSEcCtD
Sulindac—Hyperglycaemia—Carmustine—malignant glioma	0.00069	0.0102	CcSEcCtD
Sulindac—Pneumonia—Carmustine—malignant glioma	0.000686	0.0102	CcSEcCtD
Sulindac—Depression—Carmustine—malignant glioma	0.000681	0.0101	CcSEcCtD
Sulindac—Photosensitivity reaction—Temozolomide—malignant glioma	0.000675	0.00998	CcSEcCtD
Sulindac—Renal failure—Carmustine—malignant glioma	0.000671	0.00992	CcSEcCtD
Sulindac—Neuropathy peripheral—Carmustine—malignant glioma	0.000669	0.00989	CcSEcCtD
Sulindac—Hyperglycaemia—Temozolomide—malignant glioma	0.000667	0.00987	CcSEcCtD
Sulindac—Stomatitis—Carmustine—malignant glioma	0.000665	0.00984	CcSEcCtD
Sulindac—Pneumonia—Temozolomide—malignant glioma	0.000663	0.00981	CcSEcCtD
Sulindac—Depression—Temozolomide—malignant glioma	0.000658	0.00972	CcSEcCtD
Sulindac—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000654	0.00967	CcSEcCtD
Sulindac—Neuropathy peripheral—Temozolomide—malignant glioma	0.000646	0.00956	CcSEcCtD
Sulindac—Stomatitis—Temozolomide—malignant glioma	0.000643	0.00951	CcSEcCtD
Sulindac—PTGS1—telencephalon—malignant glioma	0.000626	0.00828	CbGeAlD
Sulindac—PTGS2—telencephalon—malignant glioma	0.000599	0.00791	CbGeAlD
Sulindac—Hepatitis—Temozolomide—malignant glioma	0.000592	0.00876	CcSEcCtD
Sulindac—Visual impairment—Carmustine—malignant glioma	0.00059	0.00873	CcSEcCtD
Sulindac—Visual impairment—Temozolomide—malignant glioma	0.000571	0.00844	CcSEcCtD
Sulindac—Flushing—Carmustine—malignant glioma	0.000569	0.00841	CcSEcCtD
Sulindac—Erythema multiforme—Temozolomide—malignant glioma	0.00056	0.00828	CcSEcCtD
Sulindac—Tinnitus—Temozolomide—malignant glioma	0.000552	0.00816	CcSEcCtD
Sulindac—Flushing—Temozolomide—malignant glioma	0.000549	0.00813	CcSEcCtD
Sulindac—Arrhythmia—Carmustine—malignant glioma	0.000547	0.00809	CcSEcCtD
Sulindac—Alopecia—Carmustine—malignant glioma	0.000541	0.00801	CcSEcCtD
Sulindac—Chills—Temozolomide—malignant glioma	0.000531	0.00786	CcSEcCtD
Sulindac—Alopecia—Temozolomide—malignant glioma	0.000523	0.00774	CcSEcCtD
Sulindac—Dysgeusia—Temozolomide—malignant glioma	0.000505	0.00746	CcSEcCtD
Sulindac—Vision blurred—Carmustine—malignant glioma	0.000503	0.00743	CcSEcCtD
Sulindac—ALB—brain—malignant glioma	0.000496	0.00655	CbGeAlD
Sulindac—Anaemia—Carmustine—malignant glioma	0.000493	0.00729	CcSEcCtD
Sulindac—Vision blurred—Temozolomide—malignant glioma	0.000486	0.00718	CcSEcCtD
Sulindac—Ill-defined disorder—Temozolomide—malignant glioma	0.000478	0.00707	CcSEcCtD
Sulindac—Leukopenia—Carmustine—malignant glioma	0.000477	0.00706	CcSEcCtD
Sulindac—Anaemia—Temozolomide—malignant glioma	0.000476	0.00704	CcSEcCtD
Sulindac—Angioedema—Temozolomide—malignant glioma	0.000471	0.00696	CcSEcCtD
Sulindac—PTGS2—medulla oblongata—malignant glioma	0.00047	0.00622	CbGeAlD
Sulindac—Malaise—Temozolomide—malignant glioma	0.000465	0.00687	CcSEcCtD
Sulindac—Vertigo—Temozolomide—malignant glioma	0.000463	0.00685	CcSEcCtD
Sulindac—Convulsion—Carmustine—malignant glioma	0.000462	0.00683	CcSEcCtD
Sulindac—Leukopenia—Temozolomide—malignant glioma	0.000461	0.00682	CcSEcCtD
Sulindac—Hypertension—Carmustine—malignant glioma	0.00046	0.00681	CcSEcCtD
Sulindac—Palpitations—Temozolomide—malignant glioma	0.000455	0.00674	CcSEcCtD
Sulindac—Chest pain—Carmustine—malignant glioma	0.000454	0.00671	CcSEcCtD
Sulindac—Myalgia—Carmustine—malignant glioma	0.000454	0.00671	CcSEcCtD
Sulindac—Convulsion—Temozolomide—malignant glioma	0.000447	0.0066	CcSEcCtD
Sulindac—Hypertension—Temozolomide—malignant glioma	0.000445	0.00658	CcSEcCtD
Sulindac—PTGS1—spinal cord—malignant glioma	0.000439	0.0058	CbGeAlD
Sulindac—Myalgia—Temozolomide—malignant glioma	0.000439	0.00649	CcSEcCtD
Sulindac—Arthralgia—Temozolomide—malignant glioma	0.000439	0.00649	CcSEcCtD
Sulindac—Oedema—Carmustine—malignant glioma	0.000435	0.00644	CcSEcCtD
Sulindac—Discomfort—Temozolomide—malignant glioma	0.000434	0.00641	CcSEcCtD
Sulindac—PTGS2—midbrain—malignant glioma	0.00043	0.00568	CbGeAlD
Sulindac—Thrombocytopenia—Carmustine—malignant glioma	0.000426	0.0063	CcSEcCtD
Sulindac—Tachycardia—Carmustine—malignant glioma	0.000425	0.00628	CcSEcCtD
Sulindac—Oedema—Temozolomide—malignant glioma	0.000421	0.00622	CcSEcCtD
Sulindac—Anaphylactic shock—Temozolomide—malignant glioma	0.000421	0.00622	CcSEcCtD
Sulindac—PTGS2—spinal cord—malignant glioma	0.000419	0.00554	CbGeAlD
Sulindac—Anorexia—Carmustine—malignant glioma	0.000415	0.00614	CcSEcCtD
Sulindac—Thrombocytopenia—Temozolomide—malignant glioma	0.000412	0.00609	CcSEcCtD
Sulindac—Hypotension—Carmustine—malignant glioma	0.000407	0.00601	CcSEcCtD
Sulindac—Hyperhidrosis—Temozolomide—malignant glioma	0.000407	0.00601	CcSEcCtD
Sulindac—CYP1A1—central nervous system—malignant glioma	0.000405	0.00536	CbGeAlD
Sulindac—Anorexia—Temozolomide—malignant glioma	0.000401	0.00593	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000397	0.00586	CcSEcCtD
Sulindac—Insomnia—Carmustine—malignant glioma	0.000394	0.00582	CcSEcCtD
Sulindac—Paraesthesia—Carmustine—malignant glioma	0.000391	0.00578	CcSEcCtD
Sulindac—Dyspnoea—Carmustine—malignant glioma	0.000388	0.00574	CcSEcCtD
Sulindac—Somnolence—Carmustine—malignant glioma	0.000387	0.00572	CcSEcCtD
Sulindac—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000383	0.00567	CcSEcCtD
Sulindac—Insomnia—Temozolomide—malignant glioma	0.00038	0.00563	CcSEcCtD
Sulindac—Decreased appetite—Carmustine—malignant glioma	0.000378	0.0056	CcSEcCtD
Sulindac—Paraesthesia—Temozolomide—malignant glioma	0.000378	0.00559	CcSEcCtD
Sulindac—Dyspnoea—Temozolomide—malignant glioma	0.000375	0.00555	CcSEcCtD
Sulindac—Somnolence—Temozolomide—malignant glioma	0.000374	0.00553	CcSEcCtD
Sulindac—Constipation—Carmustine—malignant glioma	0.000372	0.0055	CcSEcCtD
Sulindac—Dyspepsia—Temozolomide—malignant glioma	0.00037	0.00548	CcSEcCtD
Sulindac—Decreased appetite—Temozolomide—malignant glioma	0.000366	0.00541	CcSEcCtD
Sulindac—Fatigue—Temozolomide—malignant glioma	0.000363	0.00536	CcSEcCtD
Sulindac—Constipation—Temozolomide—malignant glioma	0.00036	0.00532	CcSEcCtD
Sulindac—Feeling abnormal—Carmustine—malignant glioma	0.000359	0.0053	CcSEcCtD
Sulindac—PTGS1—central nervous system—malignant glioma	0.000356	0.00471	CbGeAlD
Sulindac—Gastrointestinal pain—Carmustine—malignant glioma	0.000356	0.00526	CcSEcCtD
Sulindac—Feeling abnormal—Temozolomide—malignant glioma	0.000347	0.00513	CcSEcCtD
Sulindac—Body temperature increased—Carmustine—malignant glioma	0.000344	0.00509	CcSEcCtD
Sulindac—Gastrointestinal pain—Temozolomide—malignant glioma	0.000344	0.00509	CcSEcCtD
Sulindac—PTGS2—central nervous system—malignant glioma	0.00034	0.0045	CbGeAlD
Sulindac—Urticaria—Temozolomide—malignant glioma	0.000334	0.00494	CcSEcCtD
Sulindac—PTGS2—cerebellum—malignant glioma	0.000333	0.0044	CbGeAlD
Sulindac—Body temperature increased—Temozolomide—malignant glioma	0.000333	0.00492	CcSEcCtD
Sulindac—CYP1A1—brain—malignant glioma	0.000322	0.00425	CbGeAlD
Sulindac—Hypersensitivity—Carmustine—malignant glioma	0.000321	0.00474	CcSEcCtD
Sulindac—Asthenia—Carmustine—malignant glioma	0.000312	0.00462	CcSEcCtD
Sulindac—Hypersensitivity—Temozolomide—malignant glioma	0.00031	0.00458	CcSEcCtD
Sulindac—Asthenia—Temozolomide—malignant glioma	0.000302	0.00446	CcSEcCtD
Sulindac—Diarrhoea—Carmustine—malignant glioma	0.000298	0.0044	CcSEcCtD
Sulindac—Pruritus—Temozolomide—malignant glioma	0.000298	0.0044	CcSEcCtD
Sulindac—Dizziness—Carmustine—malignant glioma	0.000288	0.00426	CcSEcCtD
Sulindac—Diarrhoea—Temozolomide—malignant glioma	0.000288	0.00426	CcSEcCtD
Sulindac—PTGS1—brain—malignant glioma	0.000283	0.00374	CbGeAlD
Sulindac—Dizziness—Temozolomide—malignant glioma	0.000278	0.00411	CcSEcCtD
Sulindac—Vomiting—Carmustine—malignant glioma	0.000277	0.00409	CcSEcCtD
Sulindac—Rash—Carmustine—malignant glioma	0.000274	0.00406	CcSEcCtD
Sulindac—Dermatitis—Carmustine—malignant glioma	0.000274	0.00405	CcSEcCtD
Sulindac—Headache—Carmustine—malignant glioma	0.000273	0.00403	CcSEcCtD
Sulindac—PTGS2—brain—malignant glioma	0.00027	0.00357	CbGeAlD
Sulindac—Vomiting—Temozolomide—malignant glioma	0.000267	0.00395	CcSEcCtD
Sulindac—Rash—Temozolomide—malignant glioma	0.000265	0.00392	CcSEcCtD
Sulindac—Dermatitis—Temozolomide—malignant glioma	0.000265	0.00392	CcSEcCtD
Sulindac—Headache—Temozolomide—malignant glioma	0.000264	0.0039	CcSEcCtD
Sulindac—Nausea—Carmustine—malignant glioma	0.000259	0.00382	CcSEcCtD
Sulindac—Nausea—Temozolomide—malignant glioma	0.00025	0.00369	CcSEcCtD
Sulindac—MAPK3—Disease—EGF—malignant glioma	1.16e-05	5.34e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTGS1—malignant glioma	1.15e-05	5.33e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.15e-05	5.31e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTPN11—malignant glioma	1.15e-05	5.3e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—EGF—malignant glioma	1.15e-05	5.3e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PTPN11—malignant glioma	1.14e-05	5.27e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTK2—malignant glioma	1.13e-05	5.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—PIK3CA—malignant glioma	1.13e-05	5.21e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.12e-05	5.17e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CD—malignant glioma	1.11e-05	5.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HES1—malignant glioma	1.11e-05	5.12e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—KRAS—malignant glioma	1.11e-05	5.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NCOR1—malignant glioma	1.1e-05	5.09e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—BRAF—malignant glioma	1.1e-05	5.07e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTT1—malignant glioma	1.09e-05	5.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—TP53—malignant glioma	1.09e-05	5.04e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	1.09e-05	5.04e-05	CbGpPWpGaD
Sulindac—PTGDR2—Signaling Pathways—AKT1—malignant glioma	1.09e-05	5.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—RAF1—malignant glioma	1.09e-05	5.02e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—GSTP1—malignant glioma	1.08e-05	4.96e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—BCHE—malignant glioma	1.07e-05	4.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT2—malignant glioma	1.07e-05	4.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—FGF2—malignant glioma	1.07e-05	4.92e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT2—malignant glioma	1.06e-05	4.91e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CB—malignant glioma	1.06e-05	4.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—SLC5A5—malignant glioma	1.06e-05	4.89e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.06e-05	4.88e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—IDH2—malignant glioma	1.06e-05	4.88e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PDGFRA—malignant glioma	1.06e-05	4.88e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—PIK3CA—malignant glioma	1.05e-05	4.86e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CAT—malignant glioma	1.05e-05	4.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Cell Cycle—TP53—malignant glioma	1.03e-05	4.76e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CD—malignant glioma	1.03e-05	4.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—SPP1—malignant glioma	1.03e-05	4.73e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS1—malignant glioma	1.02e-05	4.73e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CD—malignant glioma	1.02e-05	4.72e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.02e-05	4.71e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—CXCL8—malignant glioma	1.02e-05	4.71e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.02e-05	4.71e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—PIK3CA—malignant glioma	1.02e-05	4.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—BCL2—malignant glioma	1.01e-05	4.67e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IFNG—malignant glioma	1e-05	4.63e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1e-05	4.63e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—MDM2—malignant glioma	9.98e-06	4.61e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	9.97e-06	4.6e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTT1—malignant glioma	9.97e-06	4.6e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—RAF1—malignant glioma	9.95e-06	4.59e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2B6—malignant glioma	9.94e-06	4.59e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—NCOR1—malignant glioma	9.89e-06	4.56e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CDKN2B—malignant glioma	9.88e-06	4.56e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—FGF2—malignant glioma	9.85e-06	4.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—ERBB2—malignant glioma	9.84e-06	4.54e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—IL2—malignant glioma	9.76e-06	4.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TERT—malignant glioma	9.72e-06	4.49e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CB—malignant glioma	9.71e-06	4.48e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—BCHE—malignant glioma	9.53e-06	4.4e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PDGFB—malignant glioma	9.49e-06	4.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGFR1—malignant glioma	9.44e-06	4.36e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HES1—malignant glioma	9.42e-06	4.35e-05	CbGpPWpGaD
Sulindac—PPARD—Gene Expression—AKT1—malignant glioma	9.42e-06	4.35e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—SLC5A5—malignant glioma	9.41e-06	4.34e-05	CbGpPWpGaD
Sulindac—MAPK3—Developmental Biology—AKT1—malignant glioma	9.4e-06	4.34e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NCOR1—malignant glioma	9.37e-06	4.32e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS1—malignant glioma	9.34e-06	4.31e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	9.31e-06	4.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—HIF1A—malignant glioma	9.3e-06	4.29e-05	CbGpPWpGaD
Sulindac—MAPK3—Hemostasis—AKT1—malignant glioma	9.22e-06	4.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MDM2—malignant glioma	9.21e-06	4.25e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—RAF1—malignant glioma	9.18e-06	4.24e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—RAF1—malignant glioma	9.13e-06	4.21e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—IDH1—malignant glioma	9.09e-06	4.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—ERBB2—malignant glioma	9.08e-06	4.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CAV1—malignant glioma	8.99e-06	4.15e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PDGFRA—malignant glioma	8.97e-06	4.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CB—malignant glioma	8.97e-06	4.14e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—PIK3CA—malignant glioma	8.96e-06	4.14e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL1B—malignant glioma	8.95e-06	4.13e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—IL2—malignant glioma	8.92e-06	4.12e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CB—malignant glioma	8.91e-06	4.11e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	8.9e-06	4.11e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KDR—malignant glioma	8.89e-06	4.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTGS2—malignant glioma	8.88e-06	4.1e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	8.82e-06	4.07e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SPHK1—malignant glioma	8.8e-06	4.06e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—BCHE—malignant glioma	8.68e-06	4.01e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	8.66e-06	4e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CYP2C18—malignant glioma	8.62e-06	3.98e-05	CbGpPWpGaD
Sulindac—ALB—Platelet activation, signaling and aggregation—AKT1—malignant glioma	8.61e-06	3.97e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—SLC5A5—malignant glioma	8.58e-06	3.96e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—F2—malignant glioma	8.56e-06	3.95e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FN1—malignant glioma	8.56e-06	3.95e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—GSTP1—malignant glioma	8.54e-06	3.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BAD—malignant glioma	8.46e-06	3.9e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PTEN—malignant glioma	8.39e-06	3.87e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—NOTCH1—malignant glioma	8.38e-06	3.87e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CAT—malignant glioma	8.31e-06	3.83e-05	CbGpPWpGaD
Sulindac—MAPK3—Innate Immune System—AKT1—malignant glioma	8.3e-06	3.83e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—TERT—malignant glioma	8.26e-06	3.81e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HLA-A—malignant glioma	8.26e-06	3.81e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CD80—malignant glioma	8.21e-06	3.79e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CG—malignant glioma	8.19e-06	3.78e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—APC—malignant glioma	8.19e-06	3.78e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—IL2—malignant glioma	8.18e-06	3.78e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	8.13e-06	3.75e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	8.11e-06	3.74e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGF—malignant glioma	8.1e-06	3.74e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PDGFB—malignant glioma	8.06e-06	3.72e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—CAV1—malignant glioma	8.06e-06	3.72e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTPN11—malignant glioma	8.05e-06	3.71e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	8.04e-06	3.71e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGFR1—malignant glioma	8.02e-06	3.7e-05	CbGpPWpGaD
Sulindac—ALB—Transmembrane transport of small molecules—RAF1—malignant glioma	7.9e-06	3.65e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—HIF1A—malignant glioma	7.9e-06	3.64e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—NCOR1—malignant glioma	7.85e-06	3.62e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PTEN—malignant glioma	7.75e-06	3.57e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—BRAF—malignant glioma	7.7e-06	3.55e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	7.7e-06	3.55e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.69e-06	3.55e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CAV1—malignant glioma	7.64e-06	3.52e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—GSTP1—malignant glioma	7.58e-06	3.5e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—STAT3—malignant glioma	7.5e-06	3.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT2—malignant glioma	7.5e-06	3.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—EGFR—malignant glioma	7.46e-06	3.44e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	7.4e-06	3.42e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CAT—malignant glioma	7.38e-06	3.4e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CG—malignant glioma	7.34e-06	3.39e-05	CbGpPWpGaD
Sulindac—PPARD—Metabolism—AKT1—malignant glioma	7.32e-06	3.38e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CD—malignant glioma	7.2e-06	3.32e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BAD—malignant glioma	7.18e-06	3.32e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	7.15e-06	3.3e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—NOTCH1—malignant glioma	7.12e-06	3.28e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PPARG—malignant glioma	7.08e-06	3.27e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—KRAS—malignant glioma	7.05e-06	3.25e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.01e-06	3.23e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTT1—malignant glioma	6.97e-06	3.22e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—CD80—malignant glioma	6.97e-06	3.22e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—NCOR1—malignant glioma	6.96e-06	3.21e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—APC—malignant glioma	6.96e-06	3.21e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—VEGFA—malignant glioma	6.95e-06	3.21e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—MYC—malignant glioma	6.93e-06	3.2e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—STAT3—malignant glioma	6.93e-06	3.2e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—GSTP1—malignant glioma	6.91e-06	3.19e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—FGF2—malignant glioma	6.9e-06	3.18e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGF—malignant glioma	6.88e-06	3.17e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTPN11—malignant glioma	6.84e-06	3.15e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—EGFR—malignant glioma	6.82e-06	3.15e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CAT—malignant glioma	6.72e-06	3.1e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—BRAF—malignant glioma	6.54e-06	3.02e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS1—malignant glioma	6.53e-06	3.01e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	6.51e-06	3e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—PIK3CA—malignant glioma	6.48e-06	2.99e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CD—malignant glioma	6.45e-06	2.98e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MDM2—malignant glioma	6.45e-06	2.98e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—KRAS—malignant glioma	6.44e-06	2.97e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—MYC—malignant glioma	6.44e-06	2.97e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—RAF1—malignant glioma	6.43e-06	2.97e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—CAV1—malignant glioma	6.4e-06	2.95e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT2—malignant glioma	6.37e-06	2.94e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—ERBB2—malignant glioma	6.36e-06	2.94e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—NCOR1—malignant glioma	6.35e-06	2.93e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—EGFR—malignant glioma	6.3e-06	2.91e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CB—malignant glioma	6.28e-06	2.9e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CD—malignant glioma	6.12e-06	2.82e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.11e-06	2.82e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—BCHE—malignant glioma	6.07e-06	2.8e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CXCL8—malignant glioma	6.03e-06	2.78e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—SLC5A5—malignant glioma	6e-06	2.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—KRAS—malignant glioma	5.95e-06	2.75e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—PIK3CA—malignant glioma	5.92e-06	2.73e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—KRAS—malignant glioma	5.91e-06	2.73e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—FGF2—malignant glioma	5.86e-06	2.7e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CG—malignant glioma	5.83e-06	2.69e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—CASP3—malignant glioma	5.77e-06	2.66e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—IL2—malignant glioma	5.77e-06	2.66e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—CAV1—malignant glioma	5.68e-06	2.62e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	5.67e-06	2.62e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CB—malignant glioma	5.62e-06	2.6e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PPARG—malignant glioma	5.62e-06	2.6e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	5.62e-06	2.59e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTGS2—malignant glioma	5.57e-06	2.57e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MDM2—malignant glioma	5.48e-06	2.53e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—PIK3CA—malignant glioma	5.47e-06	2.52e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—RAF1—malignant glioma	5.46e-06	2.52e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MMP9—malignant glioma	5.46e-06	2.52e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—PIK3CA—malignant glioma	5.43e-06	2.51e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PTEN—malignant glioma	5.42e-06	2.5e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.42e-06	2.5e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—ERBB2—malignant glioma	5.4e-06	2.49e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CB—malignant glioma	5.33e-06	2.46e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling by GPCR—AKT1—malignant glioma	5.29e-06	2.44e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—TP53—malignant glioma	5.25e-06	2.42e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—CAV1—malignant glioma	5.18e-06	2.39e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CG—malignant glioma	5.17e-06	2.39e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CD—malignant glioma	5.12e-06	2.36e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PPARG—malignant glioma	4.99e-06	2.3e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	4.94e-06	2.28e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	4.9e-06	2.26e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—VEGFA—malignant glioma	4.9e-06	2.26e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PTEN—malignant glioma	4.86e-06	2.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—STAT3—malignant glioma	4.85e-06	2.24e-05	CbGpPWpGaD
Sulindac—MAPK3—Immune System—AKT1—malignant glioma	4.84e-06	2.23e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—GSTP1—malignant glioma	4.83e-06	2.23e-05	CbGpPWpGaD
Sulindac—MAPK3—Gene Expression—AKT1—malignant glioma	4.81e-06	2.22e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CG—malignant glioma	4.71e-06	2.18e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CAT—malignant glioma	4.7e-06	2.17e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PTEN—malignant glioma	4.61e-06	2.13e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PPARG—malignant glioma	4.55e-06	2.1e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CD—malignant glioma	4.55e-06	2.1e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—MYC—malignant glioma	4.51e-06	2.08e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CB—malignant glioma	4.46e-06	2.06e-05	CbGpPWpGaD
Sulindac—MAPK3—Disease—AKT1—malignant glioma	4.46e-06	2.06e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—NCOR1—malignant glioma	4.44e-06	2.05e-05	CbGpPWpGaD
Sulindac—ALB—Hemostasis—AKT1—malignant glioma	4.44e-06	2.05e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—EGFR—malignant glioma	4.41e-06	2.03e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—KRAS—malignant glioma	4.17e-06	1.92e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CD—malignant glioma	4.14e-06	1.91e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—STAT3—malignant glioma	4.12e-06	1.9e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CB—malignant glioma	3.96e-06	1.83e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTGS2—malignant glioma	3.93e-06	1.81e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PTEN—malignant glioma	3.86e-06	1.78e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—MYC—malignant glioma	3.83e-06	1.77e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—PIK3CA—malignant glioma	3.83e-06	1.77e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—EGFR—malignant glioma	3.74e-06	1.73e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—TP53—malignant glioma	3.7e-06	1.71e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—CAV1—malignant glioma	3.62e-06	1.67e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CB—malignant glioma	3.61e-06	1.67e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTGS2—malignant glioma	3.58e-06	1.65e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—KRAS—malignant glioma	3.54e-06	1.63e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	3.46e-06	1.6e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—PIK3CA—malignant glioma	3.43e-06	1.58e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PTEN—malignant glioma	3.42e-06	1.58e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CG—malignant glioma	3.3e-06	1.52e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—PIK3CA—malignant glioma	3.25e-06	1.5e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PPARG—malignant glioma	3.18e-06	1.47e-05	CbGpPWpGaD
Sulindac—MAPK3—Signaling Pathways—AKT1—malignant glioma	3.13e-06	1.44e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PTEN—malignant glioma	3.12e-06	1.44e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CD—malignant glioma	2.9e-06	1.34e-05	CbGpPWpGaD
Sulindac—PTGS1—Metabolism—AKT1—malignant glioma	2.8e-06	1.29e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—PIK3CA—malignant glioma	2.72e-06	1.26e-05	CbGpPWpGaD
Sulindac—PTGS2—Disease—AKT1—malignant glioma	2.66e-06	1.23e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CB—malignant glioma	2.53e-06	1.17e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTGS2—malignant glioma	2.5e-06	1.16e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—PIK3CA—malignant glioma	2.42e-06	1.11e-05	CbGpPWpGaD
Sulindac—PTGS2—Metabolism—AKT1—malignant glioma	2.22e-06	1.03e-05	CbGpPWpGaD
Sulindac—ALB—Metabolism—PIK3CA—malignant glioma	2.2e-06	1.02e-05	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PTEN—malignant glioma	2.18e-06	1.01e-05	CbGpPWpGaD
Sulindac—CYP1A1—Metabolism—AKT1—malignant glioma	1.97e-06	9.11e-06	CbGpPWpGaD
Sulindac—ALB—Metabolism—AKT1—malignant glioma	1.8e-06	8.3e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—PIK3CA—malignant glioma	1.54e-06	7.11e-06	CbGpPWpGaD
Sulindac—CYP1A2—Metabolism—AKT1—malignant glioma	1.26e-06	5.81e-06	CbGpPWpGaD
